Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (776 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Responsible party: not given (raises risk) · Design
• Design: parallel (raises risk) · Design
• Number of arms: 5 (lowers risk) · Design
• Phase: 1 (lowers risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 112 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: bmshepatitis virusgenotypesafety tolerabilityhcv
  Phrases that lowered it: kgbmimass indexbody masspharmacokinetics of
• Sponsor's past trials: 209 (raises risk) · Sponsor's track record
• Blinding: none (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past termination rate: 7.7% (raises risk) · Sponsor's track record
• Maximum age: 60 (lowers risk) · Who can join
• Disease area, infectious disease: Yes (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects NCT00722358 · started 2008 · scored riskier than 18% of active trials completed
• A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects NCT00664625 · started 2008 · scored riskier than 24% of active trials completed
• A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects NCT00559247 · started 2008 · scored riskier than 20% of active trials completed
• Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications NCT01455090 · started 2011 · scored riskier than 15% of active trials completed
• Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care NCT01012895 · started 2009 · scored riskier than 20% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.